PBLS — Parabilis Medicines, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1657677 ·
Last close
$32.29
Market Cap
—
52W High
$42.49
52W Low
$24.51
ADV30
897,855
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 148,000 | — | -50,886,000 | -52,463,000 | 1,175,262,000 | 1,087,060,000 | 127,528,000 |
| Mar 2026 | 0 | — | -47,453,000 | -45,316,000 | 384,173,000 | 329,039,000 | 139,953,000 |
| Jun 2025 | 0 | — | -36,520,000 | -34,810,000 | — | — | — |
| Mar 2025 | 0 | — | -40,241,000 | -38,326,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-83,354,000
Investing CF
$6,320,000
Financing CF
$418,186,000
CapEx
$-443,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.16
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-586,820,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-82,951,000
Pretax Income TTM
$-83,642,000
Interest Exp TTM
$691,000
Analysts
4
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -152,079,000 | -145,889,000 | 80,820,000 | 97,344,000 | -16,524,000 | -123,713,000 |
| Dec 2024 | 0 | -126,125,000 | -117,914,000 | 149,253,000 | 92,814,000 | 56,439,000 | -103,613,000 |
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $40.00 · spot: $32.29 · call volume: 18 · put volume: 59
Expected Move to 2026-10-16:
±$5.05
(15.64%) —
implied range
$27.24 –
$37.34
· ATM straddle on $30.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.03T | $1157.08 | — |
| JNJ | JOHNSON & JOHNSON | $638.00B | $264.74 | — |
| ABBV | AbbVie Inc. | $462.26B | $261.59 | — |
| MRK | Merck & Co., Inc. | $358.50B | $145.31 | — |
| NVS | NOVARTIS AG | $270.98B | $142.57 | — |
News headlines (Yahoo Finance, 1h cache)
Sixty Degree Capital Extends Its Track Record as Five Portfolio Companies Enter the Public Markets in 2026
2026-09-28 14:00 · Yahoo
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
2026-09-01 11:00 · Yahoo
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
2026-08-25 11:00 · Yahoo
Young startups miss out on biotech venture funding rebound, MassBio says
2026-08-25 00:01 · Yahoo
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-13 11:00 · Yahoo
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
2026-09-23 12:00 · Yahoo
Parabilis Medicines (PBLS) Stock Valuation After Recent 10% Single Day Decline
2026-06-15 21:14 · Yahoo
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2026-06-11 20:05 · Yahoo
How to Play PBLS Stock After the Parabilis IPO
2026-06-11 19:12 · Yahoo
Parabilis Medicines Announces Pricing of Upsized Initial Public Offering
2026-06-10 00:22 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.